Middle East & Africa Antibody Drug Conjugates Market Size & Outlook
Middle East & Africa antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
MEA antibody drug conjugates market highlights
- The MEA antibody drug conjugates market generated a revenue of USD 66.1 million in 2021.
- The market is expected to grow at a CAGR of 22% from 2022 to 2030.
- In terms of segment, blood cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2022 to 2030.
MEA data book summary
| Market revenue in 2021 | USD 66.1 million |
| Market revenue in 2030 | USD 396.2 million |
| Growth rate | 22% (CAGR from 2021 to 2030) |
| Largest segment | Blood cancer |
| Fastest growing segment | Blood Cancer |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.1% of the global antibody drug conjugates market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 396.2 million by 2030.
Blood cancer was the largest segment with a revenue share of 52.19% in 2021. Horizon Databook has segmented the Middle East & Africa antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of chronic conditions, such as cancer, is expected to accelerate market growth. According to 2018 WHO estimates, cancer incidence in the Middle East was expected to double by 2030. It also showed that 9 out of 22 countries in this region did not have optimal or operational facilities to treat cancer.
Economic development and presence of high unmet healthcare needs especially in emerging economies such as South Africa are primary market drivers. Hence, presence of major untapped opportunities and growing need for early diagnosis are anticipated to boost the market.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
MEA antibody drug conjugates market size, by country, 2018-2030 (US$M)
Middle East & Africa Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
